BioNTech SE (BNTX) Receives a Hold from Goldman Sachs

Goldman Sachs analyst Chris Shibutani maintained a Hold rating on BioNTech SE (BNTXResearch Report) today and set a price target of $200.00. The company’s shares closed yesterday at $169.30.

Shibutani covers the Healthcare sector, focusing on stocks such as BioNTech SE, Pfizer, and Arcutis Biotherapeutics. According to TipRanks, Shibutani has an average return of 23.3% and a 48.28% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioNTech SE with a $215.11 average price target, implying a 27.06% upside from current levels. In a report released on August 1, J.P. Morgan also initiated coverage with a Hold rating on the stock with a $183.00 price target.

See today’s best-performing stocks on TipRanks >>

BNTX market cap is currently $41.14B and has a P/E ratio of 2.75.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.

Read More on BNTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More